日本デスク

Site en français

Conseils en Propriété Industrielle / European Patent and Trademark Attorneys

News

In France and abroad

Current IP News

Press Releases

Expertise

Life Sciences and Chemistry

IT / Mechanics / Physics

Focus on our EP Practice

Unitary Patent

Trademarks & Designs

Our expertise

Contracts, IP valuation & Data

Drafting of your contracts
IP asset valuation
GDPR compliance

IP Intelligence

Patentability Study
Freedom to operate
Anticipating developments

For the last 80 years, we have been assisting our clients in protecting, developing and defending their innovations and creations.

Training

IP TRAINING

IP Academy

5-day seminar

Publications

Last Published

Current IP News
published by our IP Attorneys

Search for a publication

All our articles organised
by theme, author, IP rights

Focus on

Discover a selection of our publications arranged by topic.

IPON Newsletter

Read our latest newsletter

Team

Partners

Our team

Find your contact among our employees

REGIMBEAU's Network

Our network of International Associates and our involvement in Professional Organisations

日本デスク

Japan Desk

Careers

Join us

Discover our current employment offers and send your application

Home > Publications > Search for a publication > Article

Article

Patentability of dosage requirements: towards an easing of requirements in canada

By Lazarina CHOISNEL and Cécile PUECH, French & European Patent Attorneys

In contrast to that of the United States, Canadian patent law excludes therapeutic methods from patentability on the grounds that physicians should not be hampered in their practice of medicine. However, as in many countries that also have this exclusion, it is possible to protect the use of a compound or a composition for therapeutic purposes in Canada, provided that an appropriate claim format is used.

Published on: 28th Oct 2021

Patent

Patentability

Therapeutic methods

Download the article

Click here